Combine and conquer: advantages and disadvantages of&#160;fixed-dose combination therapy (Q38046641)

27 August 2017

Combine and conquer: advantages and disadvantages of fixed-dose combination therapy (English)

1 reference

27 August 2017

D S H Bell

1

1 reference

27 August 2017

25 October 2012

1 reference

Diabetes, Obesity and Metabolism

27 August 2017

1 reference

27 August 2017

15

1 reference

27 August 2017

4

1 reference

27 August 2017

291-300

1 reference

Treatment approach and HbA1c control among US adults with type 2 diabetes: NHANES 1999-2004.

27 August 2017

1 reference

Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). UK Prospective Diabetes Study (UKPDS) Group.

21 January 2018

1 reference

Efficacy of glyburide/metformin tablets compared with initial monotherapy in type 2 diabetes

21 January 2018

1 reference

Multicenter, randomized, double-masked, parallel-group assessment of simultaneous glipizide/metformin as second-line pharmacologic treatment for patients with type 2 diabetes mellitus that is inadequately controlled by a sulfonylurea

21 January 2018

1 reference

Fixed-dose single tablet antidiabetic combinations

21 January 2018

1 reference

Practical considerations and guidelines for dosing sulfonylureas as monotherapy or combination therapy

21 January 2018

1 reference

Simultaneous glyburide/metformin therapy is superior to component monotherapy as an initial pharmacological treatment for type 2 diabetes.

21 January 2018

1 reference

Antihyperglycaemic efficacy, response prediction and dose-response relations of treatment with metformin and sulphonylurea, alone and in primary combination.

21 January 2018

1 reference

Risk of mortality and adverse cardiovascular outcomes in type 2 diabetes: a comparison of patients treated with sulfonylureas and metformin

21 January 2018

1 reference

Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies

21 January 2018

1 reference

Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials

21 January 2018

1 reference

All-cause mortality in diabetic patients treated with combinations of sulfonylureas and biguanides

21 January 2018

1 reference

A Systematic Review and Meta-Analysis of Hypoglycemia and Cardiovascular Events: A comparison of glyburide with other secretagogues and with insulin

21 January 2018

1 reference

Mortality in type 2 diabetic subjects prescribed metformin and sulphonylurea drugs in combination: cohort study

21 January 2018

1 reference

Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database.

21 January 2018

1 reference

Do sulfonylurea drugs increase the risk of cardiac events?

21 January 2018

1 reference

Sulphonylurea-metformin combination therapy, cardiovascular disease and all-cause mortality: the Fremantle Diabetes Study

21 January 2018

1 reference

Cardiovascular safety with linagliptin in patients with type 2 diabetes mellitus: a pre-specified, prospective, and adjudicated meta-analysis of a phase 3 programme

21 January 2018

1 reference

Saxagliptin for the treatment of type 2 diabetes mellitus: assessing cardiovascular data

21 January 2018

1 reference

Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion

21 January 2018

1 reference

Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1.

21 January 2018

1 reference

Cardiovascular safety of exenatide BID: an integrated analysis from controlled clinical trials in participants with type 2 diabetes

21 January 2018

1 reference

Safety and tolerability of sitagliptin in clinical studies: a pooled analysis of data from 10,246 patients with type 2 diabetes

21 January 2018

1 reference

A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes

21 January 2018

1 reference

Exogenous High-Mobility Group Box 1 Protein Induces Myocardial Regeneration After Infarction via Enhanced Cardiac C-Kit+ Cell Proliferation and Differentiation

21 January 2018

1 reference

High mobility group box 1 is a novel substrate of dipeptidyl peptidase-IV.

21 January 2018

1 reference

Future perspectives for insulinotropic agents in the treatment of type 2 diabetes-DPP-4 inhibitors and sulphonylureas

21 January 2018

1 reference

DPP-4 inhibitors in the management of type 2 diabetes: a critical review of head-to-head trials

21 January 2018

1 reference

Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes

21 January 2018

1 reference

Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis

21 January 2018

1 reference

A treatment strategy implementing combination therapy with sitagliptin and metformin results in superior glycaemic control versus metformin monotherapy due to a low rate of addition of antihyperglycaemic agents.

21 January 2018

1 reference

The effect of initial therapy with the fixed-dose combination of sitagliptin and metformin compared with metformin monotherapy in patients with type 2 diabetes mellitus.

21 January 2018

1 reference

Efficacy and safety of sitagliptin and the fixed-dose combination of sitagliptin and metformin vs. pioglitazone in drug-naïve patients with type 2 diabetes.

21 January 2018

1 reference

The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone

21 January 2018

1 reference

Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial.

21 January 2018

1 reference

Rapid insulin initiation in non-insulin-dependent diabetes mellitus

21 January 2018

1 reference

Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance

21 January 2018

1 reference

A systematic review of adherence, treatment satisfaction and costs, in fixed-dose combination regimens in type 2 diabetes

21 January 2018

1 reference

Impact of fixed-dose combination drugs on adherence to prescription medications

21 January 2018

1 reference

Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients.

21 January 2018

1 reference

Greater reductions in A1C in type 2 diabetic patients new to therapy with glyburide/metformin tablets as compared to glyburide co‐administered with metformin

21 January 2018

1 reference

Adherence to oral antidiabetic therapy in a managed care organization: a comparison of monotherapy, combination therapy, and fixed-dose combination therapy

21 January 2018

1 reference

Out-of-pocket and total costs of fixed-dose combination antihypertensives and their components

21 January 2018

1 reference

Triple oral fixed-dose diabetes polypill versus insulin plus metformin efficacy demonstration study in the treatment of advanced type 2 diabetes (TrIED study-II).

21 January 2018

1 reference

Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time?

21 January 2018

1 reference

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

21 January 2018

1 reference

Treatment intensification in patients with type 2 diabetes who failed metformin monotherapy.

21 January 2018

1 reference

Clinical inertia in response to inadequate glycemic control: do specialists differ from primary care physicians?

21 January 2018

1 reference

Clinical inertia contributes to poor diabetes control in a primary care setting

21 January 2018

1 reference

Review of current therapies for secondary hypertrophic pulmonary osteoarthropathy

21 January 2018

1 reference

Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/DOM.12015

1 reference

27 August 2017

1 reference

PubMed ID

23013323